We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
On this page, you will find the most up-to-date notices regarding current events and their impact on West Operations.
Israel - West Pharmaceutical Services, Inc. Update
West is committed to providing timely and transparent communications to all our stakeholders regarding the ongoing events in Israel and their impact to our manufacturing operations at our West Israel facilities and our overall supply chain.
Our first priority remains the safety and welfare of our team members, their families, and their communities in this region. At this time, all West sites, suppliers, and partners remain operational with no significant disruption to our manufacturing and supply chain operations, and our main logistic lanes remain open for air and sea freight.
While there is increased hostile activity occurring in the Red Sea and many major commercial shipping companies have suspended shipping in the Red Sea, this change does NOT impact West products or our suppliers at this time.
We continue to take proactive measures to mitigate risk and provide our customers with continuity of supply by accelerating shipment of all finished goods and critical components out of Israel, as well as utilizing alternative network warehouse solutions. If an order is completed early, a West team member will reach out accordingly to discuss logistics.
Our global crisis team continues to monitor this evolving situation and maintains close contact with our suppliers and logistics partners. We will keep you informed of any changes that may have implications for your business.
We are grateful and humbled by the unwavering dedication of our West Israel team and partners for their continued support of our customers and the patients they serve.
Thank you for your support and understanding as we navigate through challenges and minimize any impacts on our business operations due to these tragic events. Please contact your Account Manager or Customer Success representative if you have any specific customer inquiries or concerns.
Last Updated on January 19, 2024
Developing a SARS-CoV-2 vaccine presents numerous and unprecedented challenges; prominent among them are greatly accelerated timelines. Ordinarily for a new drug product, there is sufficient time for selection/evaluation of the vial/stopper packaging system – one that guarantees quality and safety from manufacture through delivery. This is not the case for a SARS-CoV-2 vaccine where the primary packaging system must be chosen quickly, creating a higher risk.
The need to provide vaccines for the SARS-CoV-2 pandemic has presented the pharmaceutical industry with unprecedented challenges. Among them are accelerated timelines for development/approval and unanticipated volumes for manufacture/delivery. Ordinarily for a new drug product, there is ample time for selecting the primary package system and establishing component availability.
Marisa Leuzzi, Senior Specialist, Global Communications, from our Exton Headquarters, is one of the growing number of coronavirus survivors. Her experiences with her illness is not uncommon – but what she did after her recovery to keep her family whole is remarkable.
Developing a SARS-CoV-2 vaccine presents numerous and unprecedented challenges; prominent among them are greatly accelerated timelines. Ordinarily for a new drug product, there is sufficient time for selection/evaluation of the vial/stopper packaging system – one that guarantees quality and safety from manufacture through delivery. This is not the case for a SARS-CoV-2 vaccine where the primary packaging system must be chosen quickly, creating a higher risk.
The need to provide vaccines for the SARS-CoV-2 pandemic has presented the pharmaceutical industry with unprecedented challenges. Among them are accelerated timelines for development/approval and unanticipated volumes for manufacture/delivery. Ordinarily for a new drug product, there is ample time for selecting the primary package system and establishing component availability.
Marisa Leuzzi, Senior Specialist, Global Communications, from our Exton Headquarters, is one of the growing number of coronavirus survivors. Her experiences with her illness is not uncommon – but what she did after her recovery to keep her family whole is remarkable.
English
Chinese
